FDA pushes to remove pregnancy drug, company pushes back

Oct 17, 2022, 6:31 AM | Updated: 6:49 am

WASHINGTON (AP) — The maker of the only U.S. drug intended to prevent premature births is making a last-ditch effort this week to keep its medication on the market, even as health regulators insist that it doesn’t work.

A Food and Drug Administration meeting that opened Monday comes more than two years after the agency declared the drug ineffective and called for its removal. Drugmaker Covis Pharma has challenged the agency’s conclusion, setting up the highly unusual three-day public hearing.

The meeting underscores the limits of FDA’s authority and the long, onerous process to remove a drug on the rare occasion when a company won’t do so voluntarily at the agency’s request.

The hearing will resemble a courtroom trial, with FDA staff and company scientists presenting arguments for and against the drug Makena, followed by a vote Wednesday by a panel of outside experts. FDA leaders will ultimately make the final decision whether to order a withdrawal.

About 10% of U.S. births come too early — before 37 weeks, raising the risk of serious health problems and even death in infants. Complicating the Makena debate is support from the leading U.S. obstetrics group to keep the decade-old drug available while more research is done.

“The need for an effective treatment for preterm birth is great,” the American College of Obstetricians and Gynecologists says. “Makena and its associated generics represent the only treatment currently available to obstetrician-gynecologists to help prevent this condition.”

But the FDA says existing data shows weekly injections of the drug don’t help prevent a repeat preterm birth.

“Based on the evidence shown today, Makena is not shown to be effective,” said FDA’s drug chief, Dr. Patrizia Cavazzoni, in opening remarks Monday. “Its benefit and risk profile is unfavorable and it should be withdrawn from the market.”

The dispute is likely to increase scrutiny of the agency’s so-called accelerated approval program, which allows drugs like Makena to launch based on promising early results while additional, usually larger, studies are conducted.

“Makena is being used as an example of the many different criticisms of this program,” said Rachel Sachs, a food and drug law specialist at Washington University of St. Louis. “That may not be fair to the other drugs, other diseases, other patients groups, but we’re forced to respond to the situation it presents.”

At its best, the accelerated approval program is credited with speeding the availability of breakthrough therapies for HIV and cancer. But in the last decade, the FDA has been increasingly criticized for failing to follow up on expedited drugs with incomplete or unconvincing confirmatory data, including a large number of expensive cancer medications on the market.

In recent years, the FDA’s cancer division has begun prodding companies to stop selling their drugs for uses granted under these so-called “dangling approvals.”

The FDA approved Makena in 2011 based on a small study suggesting it reduced rates of premature birth in women with a history of early deliveries. Makena consists of a synthetic version of the hormone progesterone, which helps the uterus grow and maintain a pregnancy. Women can start the shots after 16 weeks of pregnancy.

Accelerated approval was granted on the condition that Makena’s original developer, Hologic, conduct a follow-up study confirming the drug resulted in lower rates of disability and death among newborns.

But results from an international study of 1,700 women released in 2019 showed the drug neither reduced premature births — as originally thought — nor resulted in healthier outcomes for babies, while increasing the risk of blood clots, depression and other side effects in mothers.

In briefing documents released this month, the FDA said leaving Makena on the market “incurs false hopes, the risks associated with treatment, and other burdens” like excess medical spending. According to a recent federal report, the U.S. has spent $700 million on Makena since 2018 through various government programs, like Medicaid and Veterans Affairs.

The FDA opinion also applies to several generic versions of the shot.

Drugmaker Covis argues that Makena is effective and that flaws in the 2019 study obscured its benefit. The Luxembourg-based company points out that Black women are at higher risk for preterm birth, but made up just 7% of women in the international study, compared with 59% in the original U.S. study used for approval. It wants time to do another study in higher risk patients, particularly Black Americans.

A patient group set up with funding by Covis, the Preterm Birth Prevention Alliance, has made similar arguments in letters to the FDA.

“We believe there is no sound public health reason to deprive” patients and physicians of access to Makena, the company said in an emailed statement.


Follow Matthew Perrone on Twitter: @AP_FDAwriter


The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


The U.S. Supreme Court is seen, Thursday, Feb. 8, 2024, in Washington. The U.S. Supreme Court has h...

Associated Press

Supreme Court decision on Trump’s election status could come Monday morning

A SCOTUS decision could come Monday in the case about whether Trump can be kicked off the ballot over his efforts to undo his 2020 defeat.

4 hours ago

Republican presidential candidate former UN Ambassador Nikki Haley poses for a selfie after speakin...

Associated Press

Nikki Haley wins D.C. Republican primary, her first 2024 victory

Nikki Haley has won the Republican primary in the District of Columbia, notching her first victory of the 2024 campaign.

4 hours ago

An Apache group that has fought to protect land it considers sacred from a copper mining project in...

Associated Press

A US appeals court ruling could allow mine development in central Arizona on land sacred to Apaches

An Apache group that has fought to protect land from a copper mining project in central Arizona suffered a significant blow.

9 hours ago

On Friday, March 1, 2024, the U.S. Food and Drug Administration said yogurt sold in the U.S. can ma...

Associated Press

Eating yogurt may reduce risk of type 2 diabetes, FDA says

Eating at least two cups of yogurt a week might reduce the risk of type 2 diabetes, the U.S. Food and Drug Administration said.

11 hours ago

Arizona will not approve new housing construction on the fast-growing edges of metro Phoenix that r...

Associated Press

Arizona Senate passes plan to manage rural groundwater, but final success is uncertain

A plan to manage rural groundwater passed the Arizona Senate amid concerns about the availability of sufficient water for future generations.

2 days ago

A woman pauses while shopping at a Kohl's store in Clifton, N.J., Jan. 26, 2024. On Thursday, Feb. ...

Associated Press

Federal Reserve’s preferred inflation gauge picked up last month in sign of still-elevated prices

An inflation gauge favored by the Federal Reserve increased in January, the latest sign that the slowdown in U.S. consumer price increases is occurring unevenly from month to month.

3 days ago

Sponsored Articles


Midwestern University

Midwestern University Clinics: transforming health care in the valley

Midwestern University, long a fixture of comprehensive health care education in the West Valley, is also a recognized leader in community health care.


Collins Comfort Masters

Avoid a potential emergency and get your home’s heating and furnace safety checked

With the weather getting colder throughout the Valley, the best time to make sure your heating is all up to date is now. 

(KTAR News Graphic)...

Boys & Girls Clubs

KTAR launches online holiday auction benefitting Boys & Girls Clubs of the Valley

KTAR is teaming up with The Boys & Girls Clubs of the Valley for a holiday auction benefitting thousands of Valley kids.

FDA pushes to remove pregnancy drug, company pushes back